BCA Advanced Therapies https://validator.w3.org/feed/docs/rss2.html Home Our Products Our Reach Our Difference Our Donors Our Services Anticoagulants and PBMCs: How Blood Collection Chemistry Shapes Immune Cell Research   Panel Discussion by Endpoint News featuring BCA SVP of Advanced Therapies Leukoreduction System (LRS) Chambers Provide More Human Lymphocytes And Monocytes than Buffy Coats Leukopak Collection for GMP Manufacturing: A Blood Center Standardization Initiative LRS Chambers Products How LRS Chambers Enrich PBMCs During Platelet Collection Updates Factors Impacting PBMC Viability in LRS Chambers and Buffy Coats Phacilitate Advanced Therapies Week 2025 Highlights ISCT 2023 Session “Automation and Digitalization in Manufacturing” Highlights FDA Accepts Iovance Biotherapeutics’ BLA Submission 2023 Cell Therapy Accomplishments So Far LRS Chambers LifeSouth Community Blood Centers Selected to Provide Umbilical Cord Blood-Derrived CD34 Cells for ISS Mission Cord Blood Connect Calls for Abstracts New York Blood Center Unveils $50 Million Investment Fund Relationship Between the Apheresis Center and the Cell Therapy Developer Quick Facts about Blood Centers of America and its Advanced Therapies Network Challenges and Future Opportunities for CAR-T BioBridge Global Profiled 2023 Affiliate Member of AATB Legend Biotech and The Janssen Pharmaceutical Companies of Johnson & Johnson Seek Approval of Carvykti Iovance Biotherapeutics Completes their BLA Submission for Lifileucel Bluejay Diagnostics Signs Collaboration Agreement with Blood Centers of America FDA Call for Submissions BCA Sr. Vice President of Advanced Therapies to Speak at the Immuno-Oncology Summit Decentralization of Manufacturing Cell Therapies BCA Launches a New Video Showcasing Its National Network New Update of BCA Advanced Therapies Capabilities Deck Contact Us Privacy Policy Videos Home